Anasayfa » AKADEMİK ÇALIŞMALAR » ÇALIŞMA PROJELERİ

ÇALIŞMA PROJELERİ

  1. Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin’s Lymphoma: Çok uluslu çalışma yardımcı araştırıcı, 2004
  2. “Multiple myelomda risk grupları ile P-glikoprotein ekspresyonu arasındaki ilişkinin belirlenmesi”, Türk Hematoloji Derneği, 2011-11, Proje Yürütücüsü, 2011.
  3. A Randomized, Open Label, Multi Centre Study To Evaluate Patient Preference With Subcutaneous Administration of Rituximab Versus Intravenous Rituximab in Previously Untreated Patients with CD20 Diffuse Large B-Cell Lymphoma or CD20 Follicular Non Hodgkin’s Lymphoma Grades 1,2 or 3A, Çok uluslu çalışma sorumlu araştırıcı, 2014.
  4. A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma (C14012), Çok uluslu çalışma yardımcı araştırıcı, 2015.
  5. A Randomized, Multicenter, Open Label , Phase 3 Study of the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib in Combination With Obinutuzumab in Subjects with Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (PCYC-1130-CA) Pharmacyclics, Çok uluslu çalışma sorumlu araştırıcı, 2015.
  6. Double-Blind Randomized Study To Compare The Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo in Subjects with Relapsed/Refractory Indolent Lymphoma  ( protokol number: CC5013-NHL-007), Çok uluslu çalışma sorumlu araştırıcı, 2015.
  7. A Multicenter, Open-Label, Single Arm, Phase IIIB, International Study Evaluating The Safety of Obinutuzumab Alone or In Combination with Chemoterapy In Patients with Previously Unreated or Relapsed/Refractory Chronic Lymphocytic Leukemia, Çok uluslu çalışma sorumlu araştırıcı, 2014.
  8. A Phase 3, Double Blind Randomized Study To Compare The Efficacy And Safety Of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo In Subjects With Relapsed/Refractory Indolent Lymphoma, (CC-5013-NHL-007), Çok uluslu çalışma sorumlu araştırıcı, 2016.
  9. A Phase 4, Open-Label, Single- Arm of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma (C25006), Çok uluslu çalışma sorumlu araştırıcı, 2016.
  10. Phase 3, Randomized, Double Blind, Placebo Controlled, Multicenter Study to Compare The Efficacy  and Safety of Lenolidomide (CC-5013) Plus R-CHOP Chemotherapy in Subjects with Previously Untreated Activated B-cell Type Diffuse Large B-cell Lymphoma (CC-5013-DLC-002), Çok uluslu çalışma sorumlu araştırıcı, 2016.
%d blogcu bunu beğendi:
Wordpress Tema indir